Navigation Links
New York Stem Cell Foundation scientists featured for new model of Alzheimer's disease
Date:7/16/2012

NEW YORK, NY (July 16, 2012) A team of scientists at The New York Stem Cell Foundation (NYSCF) Laboratory led by Scott Noggle, PhD, NYSCFCharles Evans Senior Research Fellow for Alzheimer's Disease, has developed the first cell-based model of Alzheimer's disease (AD) by reprogramming skin cells of Alzheimer's patients to become brain cells that are affected in Alzheimer's. This will allow researchers to work directly on living brain cells suffering from Alzheimer's, which until now had not been possible. Andrew Sproul, PhD, a postdoctoral associate in Dr. Noggle's laboratory, will present this work on Thursday, July 19 at the Alzheimer's Association International Conference (AAIC) held in Vancouver.

Dr. Noggle and his team reprogrammed skin cell samples taken from twelve patients diagnosed with early-onset Alzheimer's and from healthy, genetically related individuals into induced pluripotent stem (iPS) cells, which can differentiate into any cell type. The team of scientists used these iPS cells to create cholinergic basal forebrain neurons, the brain cells that are affected in Alzheimer's. These cells recapitulate the features and cellular-level functions of patients suffering from Alzheimer's, a devastating disease that affects millions of people globally but for which there is currently no effective treatment.

NYSCF has pioneered the creation of disease models based on the derivation of human cells. Four years ago, a NYSCF-funded team created a cell-based model for ALS, or motor neuron disease, the first patient-specific stem cells created for any disease. The cell-based model for Alzheimer's builds on this earlier work.

"Patient derived AD cells will prove invaluable for future research advances, as they already have with patient-derived ALS cells," said NYSCF CEO Susan Solomon. "They will be a critical tool in the drug discovery process, as potential drugs could be tested directly on these cells. Although research on animals has provided valuable insight into AD, we aren't mice, and animals don't properly reflect the features of the disease we are trying to cure. As we work to find new drugs and treatments our research should focus on actual human sufferers of Alzheimer's disease," emphasized Ms. Solomon

This cell-based model has already led to important findings. Preliminary results of this NYSCF research, done in collaboration with Sam Gandy, MD, PhD, an international expert in the pathology of Alzheimer's at Mount Sinai School of Medicine, demonstrated differences in cellular function in Alzheimer's patients. Specifically, Alzheimer's neurons produce more of the toxic form of beta amyloid, the protein fragment that makes up amyloid plaques, than in disease-free neurons.

"iPS cell technology, along with whole genome sequencing, provide our best chance at unravelling the causes of common forms of Alzheimer's disease," noted Dr. Gandy.

"This collaboration is a great example of how NYSCF is bringing together experts in stem cell technology and clinicians to save and enhance lives by finding better treatments," Ms. Solomon explained.

The research to be reported at the AAIC by Andrew Sproul focused on stem cell models of individuals with presenilin-1 (PSEN1) mutations, a genetic cause of AD. As Dr. Sproul has said, this cell-based model could "revolutionize how we discover drugs to potentially cure Alzheimer's disease."


'/>"/>

Contact: David McKeon
dmckeon@nyscf.org
212-365-7440
New York Stem Cell Foundation
Source:Eurekalert

Related medicine news :

1. Kessler Foundations A.M. Barrett appointed to National Quality Forum Steering Committee
2. The Ben & Catherine Ivy Foundation contributes $10 million to TGen for brain cancer research
3. Damon Runyon Cancer Research Foundation grants fellowship awards to 21 top young scientists
4. Lauren Sciences LLCs research team at Ben-Gurion University awarded Campbell Foundation grant to develop a V-Smart therapeutic for neuro-HIV
5. Taxman Foundation pledges $2.5 million to boost training of digestive disease experts
6. IQware Solutions is Pleased to Announce that IQware MTM has Been Selected by the Tennessee Pharmacists Research and Education Foundation (TPREF)
7. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
8. Damon Runyon Cancer Research Foundation awards $3.3 million to 8 top young clinical investigators
9. Kessler Foundation scientists present cognitive research findings at MS dual symposium
10. Biomedical researchers receive Hartwell Foundation awards
11. Kessler Foundation researchers present at first International Congress on Cognition in MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Petersburg Florida (PRWEB) , ... March 28, 2017 , ... ... Marine Corp to raise money to for the Toys for Tots Literacy Campaign at ... federal budget in excess of $70 billion, the U.S. ranks at number 14 internationally ...
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally ... the “perfect smile.” The National Association of Dental Laboratories (NADL) is informing dentists ... be aware of when utilizing dental laboratories and technicians that create these veneers. ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System ... procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. ...
(Date:3/28/2017)... NJ (PRWEB) , ... March 28, 2017 , ... ... Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a busy ... their team of professional staff discussed strategies for preventing outbreaks among camp communities ...
(Date:3/28/2017)... ... 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader ... women’s hair loss. Although hair transplant procedures can be seen as more of a ... can be two reasons a woman may see her hair thinning. , “We are ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 ... Israel . This new business entity, Emosis Ltd, headquartered in ... research and development of novel assays complementing the mother company existing ... locally support commercialization and sales development of Emosis kits. ... This strategic move starts building ...
(Date:3/28/2017)...  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical ... other unmet medical needs, announced today two poster ... annual meeting.  The first poster to be presented ... ENMD-2076 in Combination with Anti-PD1 in Syngeneic Cancer ... presented on April 4 is entitled " Kinase ...
(Date:3/28/2017)... -- The global flow cytometry market ... 2025, according to a new study by Grand View ... cancer is expected to upsurge the demand for flow ... years. In addition, higher number of physicians is inclined ... therapy, due to adverse effects caused by chemotherapy & ...
Breaking Medicine Technology: